Pub Date : 2026-01-13eCollection Date: 2026-01-01DOI: 10.1055/a-2733-1068
Owen McKay, Joanne Lundy, Sally Bell, Phil Ha, Hugh Gao, Brendan Jenkins, Chamkaushalya Bulathsinghalage, Michael Swan, Simon Hew, Belinda Lee, Pranav Dorwal, Manoop S Bhutani, Vivek Rathi, Sean Grimmond, Andrew Perry, Trevor Wilson, Andrew Strickland, John Zalcberg, Daniel Croagh
Background and study aims: Pancreatic ductal adenocarcinoma (PDAC) is a poor prognostic malignancy. Comprehensive genomic profiling (CGP) has improved outcomes in many cancers, but widespread uptake in PDAC remains elusive. This study investigated the feasibility of using endoscopic ultrasound with fine-needle biopsy (EUS-FNB) for CGP in advanced PDAC.
Patients and methods experimental design: A multicenter prospective cohort study was conducted to assess the feasibility of using DNA and RNA extracted from fresh frozen or archival formalin-fixed paraffin-embedded (FFPE) EUS-FNB for CGP on advanced PDAC using the TSO-500 gene panel testing. Results of the CGP were reviewed at a molecular tumor board (MTB) and subsequent treatment recommendations were forwarded to the referring clinicians.
Results: CGP was successful in 129 of 143 patients (90%) enrolled between May 2020 to September 2023. Fresh frozen EUS-FNB provided suitable genetic material for CGP in 123 of 133 patients (92%). Conversely, CGP was successful on FFPE biopsy blocks from only six of 16 patients (38%). Fifty-two of 143 patients (36%) had a potentially targetable mutation detected, and eight of these patients (6%) were treated with targeted therapy based on their EUS-FNB-derived molecular profile. Patients who received personalized therapy had a significant ( P < 0.0001) increase in survival versus standard or no therapy at 12 and 36 months. Median patient survival on standard therapy was 9.47 months versus > 18 months for personalized therapy.
Conclusions: This real-world study confirms the feasibility and utility of CGP using EUS-FNB in advanced PDAC. It illustrates the importance of timely access to personalized therapy informed by CGP, which can impact the treatment pathway and improve survival outcomes.
{"title":"Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma.","authors":"Owen McKay, Joanne Lundy, Sally Bell, Phil Ha, Hugh Gao, Brendan Jenkins, Chamkaushalya Bulathsinghalage, Michael Swan, Simon Hew, Belinda Lee, Pranav Dorwal, Manoop S Bhutani, Vivek Rathi, Sean Grimmond, Andrew Perry, Trevor Wilson, Andrew Strickland, John Zalcberg, Daniel Croagh","doi":"10.1055/a-2733-1068","DOIUrl":"10.1055/a-2733-1068","url":null,"abstract":"<p><strong>Background and study aims: </strong>Pancreatic ductal adenocarcinoma (PDAC) is a poor prognostic malignancy. Comprehensive genomic profiling (CGP) has improved outcomes in many cancers, but widespread uptake in PDAC remains elusive. This study investigated the feasibility of using endoscopic ultrasound with fine-needle biopsy (EUS-FNB) for CGP in advanced PDAC.</p><p><strong>Patients and methods experimental design: </strong>A multicenter prospective cohort study was conducted to assess the feasibility of using DNA and RNA extracted from fresh frozen or archival formalin-fixed paraffin-embedded (FFPE) EUS-FNB for CGP on advanced PDAC using the TSO-500 gene panel testing. Results of the CGP were reviewed at a molecular tumor board (MTB) and subsequent treatment recommendations were forwarded to the referring clinicians.</p><p><strong>Results: </strong>CGP was successful in 129 of 143 patients (90%) enrolled between May 2020 to September 2023. Fresh frozen EUS-FNB provided suitable genetic material for CGP in 123 of 133 patients (92%). Conversely, CGP was successful on FFPE biopsy blocks from only six of 16 patients (38%). Fifty-two of 143 patients (36%) had a potentially targetable mutation detected, and eight of these patients (6%) were treated with targeted therapy based on their EUS-FNB-derived molecular profile. Patients who received personalized therapy had a significant ( <i>P</i> < 0.0001) increase in survival versus standard or no therapy at 12 and 36 months. Median patient survival on standard therapy was 9.47 months versus > 18 months for personalized therapy.</p><p><strong>Conclusions: </strong>This real-world study confirms the feasibility and utility of CGP using EUS-FNB in advanced PDAC. It illustrates the importance of timely access to personalized therapy informed by CGP, which can impact the treatment pathway and improve survival outcomes.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"14 ","pages":"a27331068"},"PeriodicalIF":2.3,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13eCollection Date: 2026-01-01DOI: 10.1055/a-2779-1774
James Turvill, Monica Haritakis, Scott Pygall, Emily Bryant, Harriet Cox, Greg Forshaw, Crispin Musicha, Victoria Allgar, Robert Logan, Mark McAlindon
Background and study aims: During the COVID-19 pandemic the National Health Service introduced colon capsule endoscopy (CCE) as an alternative to colonoscopy in patients awaiting 3-year post-polypectomy surveillance. We determined the safety, diagnostic accuracy, and utility of CCE in this clinical setting.
Patients and methods: Consenting patients awaiting 3-year post-polypectomy surveillance underwent CCE or colonoscopy. For those having CCE, risk-based guidance was developed directing to: 1) immediate colorectal endoscopic intervention; 2) deferred intervention; or 3) discharge. The safety, comparative and paired diagnostic accuracy, and colonoscopy capacity spared by CCE were determined.
Results: There were 464 CCE and 78 colonoscopy patients recruited. CCE patients were younger (mean 62 years versus 68 years). CCE was safely tolerated in 99% of patients. More ≥ 10 mm and 6- to 9-mm polyps were detected in the CCE cohort than the colonoscopy comparator cohort. This was on an intention to investigate basis and in those who had complete and adequately prepared examinations. Two hundred and five CCE patients had an urgent colonoscopy or flexible sigmoidoscopy and their paired findings were matched. Per patient sensitivities for ≥ 10 mm and 6- to 9-mm polyps were 92% and 90%, respectively. Two-thirds of patients entered a modified management pathway after CCE with 25% being discharged and 27% having a procedure deferral for up to 3 years. CCE completion and bowel preparation adequacy rates were 78% and 73% respectively. No colorectal cancer was detected.
Conclusions: CCE is a safe diagnostic of colorectal polyps. In surveillance, its "filter function" complements existing colorectal diagnostic services by providing capacity and choice.
{"title":"Multicenter study of colon capsule endoscopy in post-polypectomy surveillance.","authors":"James Turvill, Monica Haritakis, Scott Pygall, Emily Bryant, Harriet Cox, Greg Forshaw, Crispin Musicha, Victoria Allgar, Robert Logan, Mark McAlindon","doi":"10.1055/a-2779-1774","DOIUrl":"10.1055/a-2779-1774","url":null,"abstract":"<p><strong>Background and study aims: </strong>During the COVID-19 pandemic the National Health Service introduced colon capsule endoscopy (CCE) as an alternative to colonoscopy in patients awaiting 3-year post-polypectomy surveillance. We determined the safety, diagnostic accuracy, and utility of CCE in this clinical setting.</p><p><strong>Patients and methods: </strong>Consenting patients awaiting 3-year post-polypectomy surveillance underwent CCE or colonoscopy. For those having CCE, risk-based guidance was developed directing to: 1) immediate colorectal endoscopic intervention; 2) deferred intervention; or 3) discharge. The safety, comparative and paired diagnostic accuracy, and colonoscopy capacity spared by CCE were determined.</p><p><strong>Results: </strong>There were 464 CCE and 78 colonoscopy patients recruited. CCE patients were younger (mean 62 years versus 68 years). CCE was safely tolerated in 99% of patients. More ≥ 10 mm and 6- to 9-mm polyps were detected in the CCE cohort than the colonoscopy comparator cohort. This was on an intention to investigate basis and in those who had complete and adequately prepared examinations. Two hundred and five CCE patients had an urgent colonoscopy or flexible sigmoidoscopy and their paired findings were matched. Per patient sensitivities for ≥ 10 mm and 6- to 9-mm polyps were 92% and 90%, respectively. Two-thirds of patients entered a modified management pathway after CCE with 25% being discharged and 27% having a procedure deferral for up to 3 years. CCE completion and bowel preparation adequacy rates were 78% and 73% respectively. No colorectal cancer was detected.</p><p><strong>Conclusions: </strong>CCE is a safe diagnostic of colorectal polyps. In surveillance, its \"filter function\" complements existing colorectal diagnostic services by providing capacity and choice.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"14 ","pages":"a27791774"},"PeriodicalIF":2.3,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and study aims: This study aimed to assess both short-term safety and long-term outcomes of whole circumferential endoscopic submucosal dissection (WC-ESD) for esophageal squamous cell carcinoma (ESCC) with tumor length > 50 mm, and to evaluate effectiveness of aggressive prophylactic dilation combined with steroid therapy in preventing esophageal stricture.
Patients and methods: A retrospective review was conducted on 67 patients who underwent WC-ESD for superficial ESCC between 2009 and 2019 at a single Japanese center. Patients were categorized into > 50-mm and ≤ 50-mm groups. The primary endpoint was incidence of post-ESD stricture in the main analysis excluding surgery/chemoradiotherapy cases within 90 days; sensitivity analysis included all patients. Secondary endpoints were number of dilations, steroid use, and long-term survival outcomes (overall survival [OS], disease-specific survival [DSS], relapse-free survival [RFS]).
Results: Stricture incidence was not significantly different (> 50 mm vs. ≤ 50 mm: 13% vs. 18%, P = 0.708; sensitivity: 21% vs. 15%, P = 0.538). Although dilations were more frequent in the > 50-mm group (96% vs. 83%), median sessions were similar (8 vs. 7.5). Prophylactic dilation plus steroids reduced refractory strictures (25%→7%, P = 0.03). For pT1a-EP/LPM cases, 5-year OS, DSS, and RFS were 100% in both groups. In pT1a-MM/pT1b cases, survival was comparable, although OS tended to be lower with > 50-mm lesions (68.9% vs. 100%, P = 0.07).
Conclusions: WC-ESD for superficial ESCC with a tumor length > 50 mm did not increase adverse events and provided comparable long-term survival. These findings support feasibility beyond guideline limits and emphasize further refinement of stricture prevention.
背景与研究目的:本研究旨在评估肿瘤长度为bbb50 mm的食管鳞状细胞癌(ESCC)全周内镜粘膜下夹层(WC-ESD)的短期安全性和长期预后,并评价积极预防性扩张联合类固醇治疗预防食管狭窄的有效性。患者和方法:回顾性分析了2009年至2019年在日本一个中心接受WC-ESD治疗浅表ESCC的67例患者。患者分为bbb50 -mm组和≤50-mm组。主要终点为除90天内手术/放化疗病例外的esd后狭窄发生率;敏感性分析纳入所有患者。次要终点是扩张次数、类固醇使用和长期生存结果(总生存期[OS]、疾病特异性生存期[DSS]、无复发生存期[RFS])。结果:狭窄发生率无显著差异(> 50 mm vs≤50 mm: 13% vs 18%, P = 0.708;敏感性:21% vs 15%, P = 0.538)。虽然> 50-mm组的扩张更频繁(96%对83%),但中位疗程相似(8对7.5)。预防性扩张加类固醇可减少难治性狭窄(25%→7%,P = 0.03)。对于pT1a-EP/LPM病例,两组5年OS、DSS和RFS均为100%。在pT1a-MM/pT1b病例中,生存率相当,尽管> 50-mm病变的OS往往较低(68.9% vs. 100%, P = 0.07)。结论:对于肿瘤长度为bbb50 mm的浅表ESCC, WC-ESD不会增加不良事件,并提供相当的长期生存。这些发现支持超出指南限制的可行性,并强调进一步改进狭窄预防。
{"title":"Clinical outcomes of circumferential endoscopic submucosal dissection in esophageal squamous cell carcinoma > 50 mm: Retrospective cohort study.","authors":"Takakazu Miyake, Hiroaki Takahashi, Satoshi Okahara, Ayumu Takizawa, Takashi Yokoyama, Junichi Kodaira, Keisuke Ishigami, Shinji Yoshii, Hiroshi Nakase","doi":"10.1055/a-2760-6112","DOIUrl":"10.1055/a-2760-6112","url":null,"abstract":"<p><strong>Background and study aims: </strong>This study aimed to assess both short-term safety and long-term outcomes of whole circumferential endoscopic submucosal dissection (WC-ESD) for esophageal squamous cell carcinoma (ESCC) with tumor length > 50 mm, and to evaluate effectiveness of aggressive prophylactic dilation combined with steroid therapy in preventing esophageal stricture.</p><p><strong>Patients and methods: </strong>A retrospective review was conducted on 67 patients who underwent WC-ESD for superficial ESCC between 2009 and 2019 at a single Japanese center. Patients were categorized into > 50-mm and ≤ 50-mm groups. The primary endpoint was incidence of post-ESD stricture in the main analysis excluding surgery/chemoradiotherapy cases within 90 days; sensitivity analysis included all patients. Secondary endpoints were number of dilations, steroid use, and long-term survival outcomes (overall survival [OS], disease-specific survival [DSS], relapse-free survival [RFS]).</p><p><strong>Results: </strong>Stricture incidence was not significantly different (> 50 mm vs. ≤ 50 mm: 13% vs. 18%, <i>P</i> = 0.708; sensitivity: 21% vs. 15%, <i>P</i> = 0.538). Although dilations were more frequent in the > 50-mm group (96% vs. 83%), median sessions were similar (8 vs. 7.5). Prophylactic dilation plus steroids reduced refractory strictures (25%→7%, <i>P</i> = 0.03). For pT1a-EP/LPM cases, 5-year OS, DSS, and RFS were 100% in both groups. In pT1a-MM/pT1b cases, survival was comparable, although OS tended to be lower with > 50-mm lesions (68.9% vs. 100%, <i>P</i> = 0.07).</p><p><strong>Conclusions: </strong>WC-ESD for superficial ESCC with a tumor length > 50 mm did not increase adverse events and provided comparable long-term survival. These findings support feasibility beyond guideline limits and emphasize further refinement of stricture prevention.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a27606112"},"PeriodicalIF":2.3,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and study aims: Olympus's new endoscopic system, EVIS X1, features five-LED illumination and a novel complementary metal-oxide-semiconductor (CMOS) image sensor distinct from conventional charge-coupled devices (CCDs), potentially improving colorectal adenoma detection rates (ADRs). This study compared ADR and related indicators between the EVIS X1 system and the conventional EVIS LUCERA ELITE, a xenon-light system.
Patients and methods: Of 4,915 colonoscopies performed between September 2020 and April 2023, 814 EVIS X1 and 953 LUCERA cases met inclusion criteria. After propensity score matching to balance baseline characteristics, 660 patients per group were analyzed. Outcomes included ADR, polyp detection rate (PDR), adenomas per colonoscopy (APC), and polyps per colonoscopy (PPC). Subgroup analysis assessed the impact of CMOS-equipped scopes within the X1 group.
Results: ADR was slightly higher in the X1 group (36.1%) than the LUCERA group (32.1%), although not statistically significant ( P = 0.147). APC (0.77 vs. 0.61, P = 0.034) and PPC (0.95 vs. 0.75, P = 0.023) were significantly higher with X1. Within the X1 group, scopes with CMOS sensors achieved a significantly higher ADR (41.9%) compared with those without. Mean size of polyps detected was smaller with CMOS than with CCD scopes. Multivariate analysis identified age > 60 years, male sex, positive fecal occult blood test, and use of the X1 system with CMOS scopes as independent predictors of higher ADR.
Conclusions: The EVIS X1 system may have the potential to improve adenoma detection, particularly when used with CMOS sensor-equipped scopes. These findings suggest potential benefits for colorectal cancer screening, although further large-scale studies are warranted for validation.
背景和研究目的:奥林巴斯的新型内窥镜系统EVIS X1具有五led照明和一种不同于传统电荷耦合器件(ccd)的新型互补金属氧化物半导体(CMOS)图像传感器,有可能提高结直肠腺瘤的检出率(adr)。本研究比较了EVIS X1系统与传统EVIS LUCERA ELITE(氙灯系统)的ADR及相关指标。患者和方法:在2020年9月至2023年4月期间进行的4,915例结肠镜检查中,814例EVIS X1和953例LUCERA符合纳入标准。在倾向评分匹配平衡基线特征后,对每组660例患者进行分析。结果包括不良反应、息肉检出率(PDR)、每次结肠镜检查腺瘤(APC)和每次结肠镜检查息肉(PPC)。亚组分析评估了X1组内配备cmos的示波器的影响。结果:X1组不良反应(36.1%)略高于LUCERA组(32.1%),但差异无统计学意义(P = 0.147)。APC (0.77 vs. 0.61, P = 0.034)和PPC (0.95 vs. 0.75, P = 0.023)随X1的增加而升高。在X1组中,与没有CMOS传感器的示波器相比,带有CMOS传感器的示波器的ADR明显更高(41.9%)。CMOS镜下息肉平均尺寸小于CCD镜下息肉平均尺寸。多因素分析发现,年龄介于60岁之间、男性、粪便隐血试验阳性以及使用X1系统和CMOS镜检是较高ADR的独立预测因素。结论:EVIS X1系统可能具有提高腺瘤检测的潜力,特别是当与配备CMOS传感器的示波器一起使用时。这些发现提示了结直肠癌筛查的潜在益处,尽管需要进一步的大规模研究来验证。
{"title":"Comparison of adenoma detection rate using the novel 5-LED vs xenon-light endoscopic system: Propensity score matching analysis.","authors":"Tatsuhiro Ito, Satoshi Osawa, Takanori Yamada, Keisuke Inagaki, Tomohiro Takebe, Satoru Takahashi, Shunya Onoue, Kiichi Sugiura, Natsuki Ishida, Tomoharu Matsuura, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Ken Sugimoto","doi":"10.1055/a-2760-6529","DOIUrl":"10.1055/a-2760-6529","url":null,"abstract":"<p><strong>Background and study aims: </strong>Olympus's new endoscopic system, EVIS X1, features five-LED illumination and a novel complementary metal-oxide-semiconductor (CMOS) image sensor distinct from conventional charge-coupled devices (CCDs), potentially improving colorectal adenoma detection rates (ADRs). This study compared ADR and related indicators between the EVIS X1 system and the conventional EVIS LUCERA ELITE, a xenon-light system.</p><p><strong>Patients and methods: </strong>Of 4,915 colonoscopies performed between September 2020 and April 2023, 814 EVIS X1 and 953 LUCERA cases met inclusion criteria. After propensity score matching to balance baseline characteristics, 660 patients per group were analyzed. Outcomes included ADR, polyp detection rate (PDR), adenomas per colonoscopy (APC), and polyps per colonoscopy (PPC). Subgroup analysis assessed the impact of CMOS-equipped scopes within the X1 group.</p><p><strong>Results: </strong>ADR was slightly higher in the X1 group (36.1%) than the LUCERA group (32.1%), although not statistically significant ( <i>P</i> = 0.147). APC (0.77 vs. 0.61, <i>P</i> = 0.034) and PPC (0.95 vs. 0.75, <i>P</i> = 0.023) were significantly higher with X1. Within the X1 group, scopes with CMOS sensors achieved a significantly higher ADR (41.9%) compared with those without. Mean size of polyps detected was smaller with CMOS than with CCD scopes. Multivariate analysis identified age > 60 years, male sex, positive fecal occult blood test, and use of the X1 system with CMOS scopes as independent predictors of higher ADR.</p><p><strong>Conclusions: </strong>The EVIS X1 system may have the potential to improve adenoma detection, particularly when used with CMOS sensor-equipped scopes. These findings suggest potential benefits for colorectal cancer screening, although further large-scale studies are warranted for validation.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a27606529"},"PeriodicalIF":2.3,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-19eCollection Date: 2025-01-01DOI: 10.1055/a-2760-6455
Gabriel Marcellier, Birane Beye, Nathaniel Edery, Alain Berson, Benedicte Jais, Paul Rivallin, Frédéric Prat
Background and study aims: Esophageal refractory benign strictures are challenging to manage. Fully-covered metallic stents (FCSEMS) are swiftly efficient but subject to high migration rates. Because new through-the-scope suturing devices (TTSS) are now available, an alternative to over-the-scope/through-the-scope clips (OTSC/TTSC) or over-the-scope suturing devices (OTSS) can be trialed to anchor FCSEMS and prevent their dislodgement.
Methods: We performed a preclinical comparison on a porcine model of the ability to prevent FCSEMS migration with TTSS, OTSC, and TTSC. Given the promising results, we then performed stent anchoring with TTSS to selected patients with refractory benign strictures. We hereby present these initial procedures and their outcomes.
Results: In preclinical trials, TTSS provided significantly higher resistance to traction than OTSC, TTSC, and no anchoring. We performed eight FCSEMS anchoring with TTSS among six patients, with encouraging technical and clinical outcomes.
Conclusions: This is the first preclinical and clinical description of the benefits of TTSS for FCSEMS anchoring in esophageal refractory benign strictures. Safe and efficient anchoring with TTSS could allow using double-silicon-layered FCSEMS that can be left in place several months for management of refractory benign strictures. This work paves the way for prospective studies assessing FCSEMS anchoring with TTSS.
{"title":"Anchoring of esophageal stents with through-the-scope suturing devices: Preclinical proof of concept and first clinical cases.","authors":"Gabriel Marcellier, Birane Beye, Nathaniel Edery, Alain Berson, Benedicte Jais, Paul Rivallin, Frédéric Prat","doi":"10.1055/a-2760-6455","DOIUrl":"10.1055/a-2760-6455","url":null,"abstract":"<p><strong>Background and study aims: </strong>Esophageal refractory benign strictures are challenging to manage. Fully-covered metallic stents (FCSEMS) are swiftly efficient but subject to high migration rates. Because new through-the-scope suturing devices (TTSS) are now available, an alternative to over-the-scope/through-the-scope clips (OTSC/TTSC) or over-the-scope suturing devices (OTSS) can be trialed to anchor FCSEMS and prevent their dislodgement.</p><p><strong>Methods: </strong>We performed a preclinical comparison on a porcine model of the ability to prevent FCSEMS migration with TTSS, OTSC, and TTSC. Given the promising results, we then performed stent anchoring with TTSS to selected patients with refractory benign strictures. We hereby present these initial procedures and their outcomes.</p><p><strong>Results: </strong>In preclinical trials, TTSS provided significantly higher resistance to traction than OTSC, TTSC, and no anchoring. We performed eight FCSEMS anchoring with TTSS among six patients, with encouraging technical and clinical outcomes.</p><p><strong>Conclusions: </strong>This is the first preclinical and clinical description of the benefits of TTSS for FCSEMS anchoring in esophageal refractory benign strictures. Safe and efficient anchoring with TTSS could allow using double-silicon-layered FCSEMS that can be left in place several months for management of refractory benign strictures. This work paves the way for prospective studies assessing FCSEMS anchoring with TTSS.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a27606455"},"PeriodicalIF":2.3,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-16eCollection Date: 2025-01-01DOI: 10.1055/a-2760-6753
Elena De Cristofaro, Federico Barbaro, Jérôme Rivory, Alexandru Lupu, Benedetto Neri, Dario Biasutto, Gianluca Andrisani, Rui Morais, Franscisco Mendes, João Santos-Antunes, Germana de Nucci, Sandro Sferrazza, Silvia Pecere, Yanis Dahel, Jean-Philippe Ratone, Laura Rovedatti, Cristiano Spada, Francesco Maria Di Matteo, Andrea Anderloni, Philippe Leclercq, Samanta Romeo, Guido Manfredi, Elisa Stasi, Jeremie Jacques, Edoardo Troncone, Lucile Héroin, Jerome Maitre, Arthur Berger, Giulio Antonelli, Simona Agazzi, Giovanna Del Vecchio Blanco, Giovanni Monteleone, Mathieu Pioche
Background and study aims: Esophagogastric junction (EGJ) lesions are uncommon and histologically diverse. Among these, EGJ hyperplastic lesions are rare and generally considered benign. However, their nonspecific appearance makes accurate endoscopic identification challenging. Endoscopic resection is both a diagnostic and therapeutic approach, yet risk factors for neoplastic transformation in EGJ lesions remain unclear. This study aimed to identify predictive factors for neoplastic transformation in hyperplastic EGJ lesions.
Patients and methods: This multicenter, retrospective study included patients with hyperplastic EGJ lesions endoscopically resected across 13 European hospitals. Data were collected from endoscopy and pathology reports. Neoplastic transformation was defined by presence of dysplasia or adenocarcinoma. A multivariable logistic regression model was conducted to assess predictive factors for neoplastic transformation in resected hyperplastic lesions.
Results: From January 2015 to October 2024, 91 EGJ hyperplastic lesions were included. Polypectomy/endoscopic mucosal resection (EMR) was performed in 86% of cases, endoscopic submucosal dissection (ESD) in 19%. En bloc resection was successfully achieved in 93% of cases, whereas R0 resection rates were confirmed in 84% of cases. Twenty-one lesions (23%) showed neoplastic transformation on histology. Independent predictive factors for neoplastic transformation in hyperplastic lesions included non-polypoid morphology (odds ratio [OR] 5.48; P = 0.025), presence of surface ulceration (OR 11.5; P = 0.0005) and lesion size (OR 5.48; P = 0.021). Lesion size > 12 mm was identified as a significant predictor of neoplastic transformation in hyperplastic lesions.
Conclusions: EGJ hyperplastic lesions showed a non-negligible risk of neoplastic transformation. These findings highlight the need for careful endoscopic assessment to predict malignancy while promoting appropriate management strategies to ensure adequate R0 resection in case of undetected local malignancy.
背景与研究目的:食管胃交界(EGJ)病变罕见且组织学多样。其中,EGJ增生性病变是罕见的,一般认为是良性的。然而,它们的非特异性外观使得准确的内窥镜识别具有挑战性。内镜切除是一种诊断和治疗方法,但EGJ病变肿瘤转化的危险因素尚不清楚。本研究旨在确定增生性EGJ病变肿瘤转化的预测因素。患者和方法:这项多中心、回顾性研究纳入了13家欧洲医院经内镜切除的EGJ增生性病变患者。数据来源于内窥镜检查和病理报告。肿瘤转化的定义是存在不典型增生或腺癌。采用多变量logistic回归模型评估切除的增生性病变中肿瘤转化的预测因素。结果:2015年1月至2024年10月共纳入91例EGJ增生性病变。息肉切除术/内镜下粘膜切除术(EMR)占86%,内镜下粘膜剥离(ESD)占19%。整体切除在93%的病例中成功实现,而R0切除率在84%的病例中得到确认。组织学上表现为肿瘤转化21例(23%)。增生性病变中肿瘤转化的独立预测因素包括非息肉样形态(比值比[OR] 5.48; P = 0.025)、有无表面溃疡(比值比[OR] 11.5; P = 0.0005)和病变大小(比值比[OR] 5.48; P = 0.021)。病变大小bbb12mm被认为是增生性病变中肿瘤转化的重要预测因子。结论:EGJ增生性病变具有不可忽视的肿瘤转化风险。这些发现强调需要仔细的内镜评估来预测恶性肿瘤,同时促进适当的管理策略,以确保在未发现局部恶性肿瘤的情况下进行充分的R0切除。
{"title":"Neoplastic risk in hyperplastic esophagogastric junction lesions: Comprehensive multicenter study.","authors":"Elena De Cristofaro, Federico Barbaro, Jérôme Rivory, Alexandru Lupu, Benedetto Neri, Dario Biasutto, Gianluca Andrisani, Rui Morais, Franscisco Mendes, João Santos-Antunes, Germana de Nucci, Sandro Sferrazza, Silvia Pecere, Yanis Dahel, Jean-Philippe Ratone, Laura Rovedatti, Cristiano Spada, Francesco Maria Di Matteo, Andrea Anderloni, Philippe Leclercq, Samanta Romeo, Guido Manfredi, Elisa Stasi, Jeremie Jacques, Edoardo Troncone, Lucile Héroin, Jerome Maitre, Arthur Berger, Giulio Antonelli, Simona Agazzi, Giovanna Del Vecchio Blanco, Giovanni Monteleone, Mathieu Pioche","doi":"10.1055/a-2760-6753","DOIUrl":"10.1055/a-2760-6753","url":null,"abstract":"<p><strong>Background and study aims: </strong>Esophagogastric junction (EGJ) lesions are uncommon and histologically diverse. Among these, EGJ hyperplastic lesions are rare and generally considered benign. However, their nonspecific appearance makes accurate endoscopic identification challenging. Endoscopic resection is both a diagnostic and therapeutic approach, yet risk factors for neoplastic transformation in EGJ lesions remain unclear. This study aimed to identify predictive factors for neoplastic transformation in hyperplastic EGJ lesions.</p><p><strong>Patients and methods: </strong>This multicenter, retrospective study included patients with hyperplastic EGJ lesions endoscopically resected across 13 European hospitals. Data were collected from endoscopy and pathology reports. Neoplastic transformation was defined by presence of dysplasia or adenocarcinoma. A multivariable logistic regression model was conducted to assess predictive factors for neoplastic transformation in resected hyperplastic lesions.</p><p><strong>Results: </strong>From January 2015 to October 2024, 91 EGJ hyperplastic lesions were included. Polypectomy/endoscopic mucosal resection (EMR) was performed in 86% of cases, endoscopic submucosal dissection (ESD) in 19%. En bloc resection was successfully achieved in 93% of cases, whereas R0 resection rates were confirmed in 84% of cases. Twenty-one lesions (23%) showed neoplastic transformation on histology. Independent predictive factors for neoplastic transformation in hyperplastic lesions included non-polypoid morphology (odds ratio [OR] 5.48; <i>P</i> = 0.025), presence of surface ulceration (OR 11.5; <i>P</i> = 0.0005) and lesion size (OR 5.48; <i>P</i> = 0.021). Lesion size > 12 mm was identified as a significant predictor of neoplastic transformation in hyperplastic lesions.</p><p><strong>Conclusions: </strong>EGJ hyperplastic lesions showed a non-negligible risk of neoplastic transformation. These findings highlight the need for careful endoscopic assessment to predict malignancy while promoting appropriate management strategies to ensure adequate R0 resection in case of undetected local malignancy.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a27606753"},"PeriodicalIF":2.3,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and study aims: This study aimed to develop a clinical prediction model to assess the 24-hour post-ERCP complication risk in patients with common bile duct stones (CBDs), guiding clinical decision-making for ERCP as a day surgery.
Patients and methods: Retrospective data from The First Hospital of Lanzhou University (2010-2019) and prospective multicenter data on post-ERCP complications (2020-2023) were collected and registered on ClinicalTrials.gov (NCT04234126, NCT04242394). The ADASYN method was used for dataset balancing. Machine learning algorithms, including KNN, XGBoost, RF, SVM, and NB, were compared with traditional models. External validation was performed with retrospective data from other ERCP centers (2015-2017) and The First Hospital of Lanzhou University (2019-2020), with registration under NCT02510495. The optimal model was selected based on the ROC curve (AUC), and an online prediction tool was developed.
Results: A logistic regression (LR) model incorporating seven feature variables-mechanical lithotripsy, pancreatic duct cannulation, bile duct dilation, residual stones, white blood cell count, alanine aminotransferase (ALT) level, and pancreatic duct stent placement-was identified as the optimal model, The model yielded specificity, sensitivity, accuracy, and AUC values of 0.835, 0.655, 0.807, and 0.819 in the external validation set, with a second external validation set providing additional results of 0.799, 0.714, 0.784, and 0.805. Patients were stratified into high- and low-risk groups. An online calculator was developed ( https://borujin.shinyapps.io/dynnomapp/ ).
Conclusions: The results indicate that the proposed LR model, utilizing the top seven risk factors, could serve as an effective tool for predicting occurrence of complications in day surgery.
{"title":"Identifying high-risk patients having ERCP as a day surgery with an online prediction platform: Multicohort validation of a machine learning model.","authors":"Boru Jin, Yi Wang, Xu Zhang, Jinyu Zhao, Wangping He, Kecheng Jin, Zhen Liu, Ruyang Zhong, Yuhu Ma, Chunlu Dong, Yanyan Lin, Xiaoliang Zhu, Kexiang Zhu, Lei Zhang, Ping Yue, Shuyan Li, Jinqiu Yuan, Xun Li, Wenbo Meng","doi":"10.1055/a-2733-1387","DOIUrl":"10.1055/a-2733-1387","url":null,"abstract":"<p><strong>Background and study aims: </strong>This study aimed to develop a clinical prediction model to assess the 24-hour post-ERCP complication risk in patients with common bile duct stones (CBDs), guiding clinical decision-making for ERCP as a day surgery.</p><p><strong>Patients and methods: </strong>Retrospective data from The First Hospital of Lanzhou University (2010-2019) and prospective multicenter data on post-ERCP complications (2020-2023) were collected and registered on ClinicalTrials.gov (NCT04234126, NCT04242394). The ADASYN method was used for dataset balancing. Machine learning algorithms, including KNN, XGBoost, RF, SVM, and NB, were compared with traditional models. External validation was performed with retrospective data from other ERCP centers (2015-2017) and The First Hospital of Lanzhou University (2019-2020), with registration under NCT02510495. The optimal model was selected based on the ROC curve (AUC), and an online prediction tool was developed.</p><p><strong>Results: </strong>A logistic regression (LR) model incorporating seven feature variables-mechanical lithotripsy, pancreatic duct cannulation, bile duct dilation, residual stones, white blood cell count, alanine aminotransferase (ALT) level, and pancreatic duct stent placement-was identified as the optimal model, The model yielded specificity, sensitivity, accuracy, and AUC values of 0.835, 0.655, 0.807, and 0.819 in the external validation set, with a second external validation set providing additional results of 0.799, 0.714, 0.784, and 0.805. Patients were stratified into high- and low-risk groups. An online calculator was developed ( https://borujin.shinyapps.io/dynnomapp/ ).</p><p><strong>Conclusions: </strong>The results indicate that the proposed LR model, utilizing the top seven risk factors, could serve as an effective tool for predicting occurrence of complications in day surgery.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a27331387"},"PeriodicalIF":2.3,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12817187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
[This corrects the article DOI: 10.1055/a-2733-3468.].
[这更正了文章DOI: 10.1055/a-2733-3468]。
{"title":"Correction: Biliary stents reshape the bile microbiome in the absence of cholangitis.","authors":"Atsuto Kayashima, Seiichiro Fukuhara, Kentaro Miyamoto, Eisuke Iwasaki, Motohiko Kato, Tomohisa Sujino","doi":"10.1055/a-2772-3924","DOIUrl":"https://doi.org/10.1055/a-2772-3924","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1055/a-2733-3468.].</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a27723924"},"PeriodicalIF":2.3,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-09eCollection Date: 2025-01-01DOI: 10.1055/a-2752-2591
Mo Thoufeeq, Ahmad Thaika, Shyam Moudhgalya, Pradeep Mundre, Vasitha Abeysuriya, Nilanga Nishad
Background and study aims: This study aimed to evaluate interobserver and intraobserver agreement in Size/Morphology/Site/Access (SMSA) scoring among practicing endoscopists with varying levels of experience.
Patients and methods: A total of 102 fully independent endoscopists participated in the study. Ten short video clips of colonic polyps of varying size and complexity were recorded using Olympus 290 colonoscopes and included white light, near focus, narrow band imaging, and chromoendoscopy where applicable. These videos were embedded in an online questionnaire. Endoscopists were asked to assign SMSA scores based on three variables-size, morphology, and access-with the site provided for standardization. A subgroup of five participants repeated the assessment after 2 to 3 weeks to evaluate intraobserver consistency. Data were analyzed using Fleiss' kappa via SPSS (v26), and Kappa interpretation followed the Landis and Koch classification.
Results: Overall interobserver agreement for SMSA level across all participants was fair (κ = 0.346). Among individual parameters, morphology had the highest agreement (κ = 0.505, moderate), followed by access (κ = 0.408, moderate) and size (κ = 0.241, fair). Subgroup analysis of experienced endoscopists (> 1000 lifetime colonoscopies) yielded slightly improved kappa values, with morphology still demonstrating the highest consistency. Intraobserver agreement showed moderate to almost perfect reliability for size (κ = 0.444 to 1.000) and moderate to substantial agreement for SMSA level (κ = 0.429 to 0.846).
Conclusions: Morphology was the most consistently scored parameter. Although the SMSA tool remains valuable, efforts such as standardized training and simplification of variable categories may be warranted to improve interobserver consistency and enhance clinical-utility.
{"title":"Is size, morphology, site, and access scoring system consistent between endoscopists? Interobserver and intraobserver polyp assessment study.","authors":"Mo Thoufeeq, Ahmad Thaika, Shyam Moudhgalya, Pradeep Mundre, Vasitha Abeysuriya, Nilanga Nishad","doi":"10.1055/a-2752-2591","DOIUrl":"10.1055/a-2752-2591","url":null,"abstract":"<p><strong>Background and study aims: </strong>This study aimed to evaluate interobserver and intraobserver agreement in Size/Morphology/Site/Access (SMSA) scoring among practicing endoscopists with varying levels of experience.</p><p><strong>Patients and methods: </strong>A total of 102 fully independent endoscopists participated in the study. Ten short video clips of colonic polyps of varying size and complexity were recorded using Olympus 290 colonoscopes and included white light, near focus, narrow band imaging, and chromoendoscopy where applicable. These videos were embedded in an online questionnaire. Endoscopists were asked to assign SMSA scores based on three variables-size, morphology, and access-with the site provided for standardization. A subgroup of five participants repeated the assessment after 2 to 3 weeks to evaluate intraobserver consistency. Data were analyzed using Fleiss' kappa via SPSS (v26), and Kappa interpretation followed the Landis and Koch classification.</p><p><strong>Results: </strong>Overall interobserver agreement for SMSA level across all participants was fair (κ = 0.346). Among individual parameters, morphology had the highest agreement (κ = 0.505, moderate), followed by access (κ = 0.408, moderate) and size (κ = 0.241, fair). Subgroup analysis of experienced endoscopists (> 1000 lifetime colonoscopies) yielded slightly improved kappa values, with morphology still demonstrating the highest consistency. Intraobserver agreement showed moderate to almost perfect reliability for size (κ = 0.444 to 1.000) and moderate to substantial agreement for SMSA level (κ = 0.429 to 0.846).</p><p><strong>Conclusions: </strong>Morphology was the most consistently scored parameter. Although the SMSA tool remains valuable, efforts such as standardized training and simplification of variable categories may be warranted to improve interobserver consistency and enhance clinical-utility.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a27522591"},"PeriodicalIF":2.3,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12704510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-09eCollection Date: 2025-01-01DOI: 10.1055/a-2752-2380
André Sasse, Thomas Roland Heiduk, Marvin Scheunemann, Lukas Hiebel, Richard F Knoop, Marius Adler, Ali Seif Amir Hosseini, Edris Wedi, Imke Amanzada, Volker Ellenrieder, Golo Petzold, Ahmad Amanzada
Background and study aims: Emergency endoscopic interventions for upper gastrointestinal hemorrhage are frequently hampered by presence of blood clots and food debris. This study aimed to assess whether integration of an additional suction channel (ASC) onto a standard gastroscope enhances efficiency of aspirating clots and viscous fluids.
Patients and methods: A 5.3-mm suction catheter was used as an ASC mounted on a 2.8-mm standard gastroscope. Suction efficacy was evaluated using gastroscopes with working channel diameters of 2.8 mm, 3.7 mm, and 6 mm in vitro. Defined volumes of water, fruit yogurt, and coagulated blood were aspirated, and time required for complete evacuation was measured. Each setup was tested with and without the BioVac system.
Results: The ASC significantly enhanced suction performance across all test media. Notably, the 2.8-mm gastroscope with ASC outperformed all other configurations in aspirating water and yogurt. For clotted blood, the ASC significantly improved evacuation times compared with all other setups besides 6-mm + BioVac.
Conclusions: A standard gastroscope equipped with an ASC significantly enhances suction performance in an in vitro model, outperforming gastroscopes with larger working channels. These findings warrant further validation in an ex vivo model to determine their clinical applicability.
{"title":"Enhancing emergency endoscopy efficiency with an additional suction channel: In vitro assessment.","authors":"André Sasse, Thomas Roland Heiduk, Marvin Scheunemann, Lukas Hiebel, Richard F Knoop, Marius Adler, Ali Seif Amir Hosseini, Edris Wedi, Imke Amanzada, Volker Ellenrieder, Golo Petzold, Ahmad Amanzada","doi":"10.1055/a-2752-2380","DOIUrl":"10.1055/a-2752-2380","url":null,"abstract":"<p><strong>Background and study aims: </strong>Emergency endoscopic interventions for upper gastrointestinal hemorrhage are frequently hampered by presence of blood clots and food debris. This study aimed to assess whether integration of an additional suction channel (ASC) onto a standard gastroscope enhances efficiency of aspirating clots and viscous fluids.</p><p><strong>Patients and methods: </strong>A 5.3-mm suction catheter was used as an ASC mounted on a 2.8-mm standard gastroscope. Suction efficacy was evaluated using gastroscopes with working channel diameters of 2.8 mm, 3.7 mm, and 6 mm in vitro. Defined volumes of water, fruit yogurt, and coagulated blood were aspirated, and time required for complete evacuation was measured. Each setup was tested with and without the BioVac system.</p><p><strong>Results: </strong>The ASC significantly enhanced suction performance across all test media. Notably, the 2.8-mm gastroscope with ASC outperformed all other configurations in aspirating water and yogurt. For clotted blood, the ASC significantly improved evacuation times compared with all other setups besides 6-mm + BioVac.</p><p><strong>Conclusions: </strong>A standard gastroscope equipped with an ASC significantly enhances suction performance in an in vitro model, outperforming gastroscopes with larger working channels. These findings warrant further validation in an ex vivo model to determine their clinical applicability.</p>","PeriodicalId":11671,"journal":{"name":"Endoscopy International Open","volume":"13 ","pages":"a27522380"},"PeriodicalIF":2.3,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}